PEB Stock Overview
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Pacific Edge Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$0.082 |
| 52 Week High | NZ$0.38 |
| 52 Week Low | NZ$0.07 |
| Beta | 1.01 |
| 1 Month Change | 3.80% |
| 3 Month Change | -5.75% |
| 1 Year Change | -78.42% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| PEB | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -3.5% | 2.0% | 3.1% |
| 1Y | -78.4% | -6.8% | 8.1% |
Return vs Industry: PEB underperformed the Australian Biotechs industry which returned -6.8% over the past year.
Return vs Market: PEB underperformed the Australian Market which returned 8.1% over the past year.
Price Volatility
| PEB volatility | |
|---|---|
| PEB Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: PEB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PEB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 114 | Peter Meintjes | www.pacificedgedx.com |
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. The company operates in two segments, Commercial and Research. It offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer.
Pacific Edge Limited Fundamentals Summary
| PEB fundamental statistics | |
|---|---|
| Market cap | AU$68.89m |
| Earnings (TTM) | -AU$28.88m |
| Revenue (TTM) | AU$23.29m |
3.0x
P/S Ratio-2.4x
P/E RatioIs PEB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEB income statement (TTM) | |
|---|---|
| Revenue | NZ$25.52m |
| Cost of Revenue | NZ$11.02m |
| Gross Profit | NZ$14.50m |
| Other Expenses | NZ$46.14m |
| Earnings | -NZ$31.65m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
May 20, 2024
| Earnings per share (EPS) | -0.039 |
| Gross Margin | 56.80% |
| Net Profit Margin | -124.01% |
| Debt/Equity Ratio | 0% |
How did PEB perform over the long term?
See historical performance and comparison